GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 898 | | ||
| | £13.4950 | 1,492 | | ||
| | £13.4950 | 1,686
| | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
4,076 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2025 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $33.7500 | 495 | | ||
| | | | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Julie Brown | |||
| b) | Position/status | Chief Financial Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 643 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
|
Aggregated volume Price |
| ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Diana Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 141 | | ||
| | £13.4950 | 272 | | ||
| | £13.4950 | 425 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
838 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 174 | | ||
| | £13.4950 | 264 | | ||
| | £13.4950 | 430 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
868 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Sally Jackson | |||
| b) | Position/status | SVP, Global Communications and CEO Office | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 81 | | ||
| | £13.4950 | 164 | | ||
| | £13.4950 | 267 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
512 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Luke Miels | |||
| b) | Position/status | Chief Commercial Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 295 | | ||
| | £13.4950 | 801 | | ||
| | £13.4950 | 636 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
1,732 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2025 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $33.7500 | 130 | | ||
| | $33.7500 | 203 | | ||
| | $33.7500 | 30 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
363 $33.7500 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | David Redfern | |||
| b) | Position/status | President, Corporate Development | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 368 | | ||
| | £13.4950 | 196 | | ||
| | £13.4950 | 510 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
1,074 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Regis Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 178 | | ||
| | £13.4950 | 295 | | ||
| | £13.4950 | 614 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
1,087 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Philip Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 123 | | ||
| | £13.4950 | 193 | | ||
| | £13.4950 | 343 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
| Aggregated volume Price | 659 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Deborah Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | £13.4950 | 471 | | ||
| | £13.4950 | 531 | | ||
| | £13.4950 | 130 | | ||
| | | | | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
1,132 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Tony Wood | |||
| b) | Position/status | Chief Scientific Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s)
| | Price(s) | Volume(s) | |
| | £13.4950 | 223 |
| ||
| | £13.4950 | 654 | | ||
| | |
| | ||
| d) | Aggregated information
| | |||
|
Aggregated volume Price |
877 £13.4950 | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | |||||
| a) | Name | Emma Walmsley | ||||
| b) | Position/status | Chief Executive Officer | ||||
| c) | Initial notification/ amendment | Initial notification | ||||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | GSK plc | ||||
| b) | LEI | 5493000HZTVUYLO1D793 | ||||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| ||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2025 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information Aggregated volume Price | N/A (single transaction)
| ||||
| e) | Date of the transaction | 2025-01-14 | ||||
| f) | Place of the transaction
| London Stock Exchange (XLON) | ||||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Hal Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
| |||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 January 2025 | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $32.1317 | 3445.486 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | James Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
| |||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 January 2025 | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $32.1317 | 371.810
| | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Shobie Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
| |||
| b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 January 2025 | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $32.1317 | 183.525 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-01-14 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
